goralatide has been researched along with Kidney Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kanasaki, K | 1 |
| Carretero, OA; Kumar, N; Liao, TD; Nakagawa, P; Peterson, EL; Romero, CA; Worou, ME | 1 |
| Brolin, TJ; Carretero, OA; Chun, B; Fogo, AB; Kazi, N; Kon, V; Ma, LJ; Myöhänen, T; Orhan, D; Potthoff, SA; Rhaleb, NE; Yang, HC; Zuo, Y | 1 |
| Kanasaki, K; Kanasaki, M; Koya, D; Nagai, T; Nitta, K | 1 |
| Chan, GC; Huang, XR; Lan, HY; Lin, M; Tang, SC; Wong, DW; Wu, HJ; Yiu, WH | 1 |
| Chan, GCW; Chan, KW; Huang, XR; Lai, KN; Lan, HY; Tang, SCW; Wu, HJ; Yiu, WH; Zou, A | 1 |
| Basha, H; Carretero, OA; Janic, B; Liao, TD; Masjoan-Juncos, JX; Nakagawa, P; Peterson, EL; Romero, CA; Worou, ME | 1 |
| Fogo, AB; Ma, LJ | 1 |
3 review(s) available for goralatide and Kidney Diseases
| Article | Year |
|---|---|
N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects.
Topics: Animals; Diabetes Complications; Fibrosis; Humans; Kidney; Kidney Diseases; Oligopeptides; Peptidyl-Dipeptidase A; Signal Transduction | 2020 |
The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Fibrosis; Humans; Kidney Diseases; Oligopeptides | 2015 |
PAI-1 and kidney fibrosis.
Topics: Angiotensins; Animals; Chronic Disease; Disease Models, Animal; Fibrosis; Humans; Kidney Diseases; Mice; Oligopeptides; Organ Specificity; Plasminogen Activator Inhibitor 1; Renin-Angiotensin System; Thymosin; Transforming Growth Factor beta1 | 2009 |
5 other study(ies) available for goralatide and Kidney Diseases
| Article | Year |
|---|---|
Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.
Topics: Animals; Disease Models, Animal; Fibrosis; Kidney Diseases; Kidney Medulla; Male; Metalloendopeptidases; Nephrons; Oligopeptides; Prolyl Oligopeptidases; Rats, Sprague-Dawley; Serine Endopeptidases; Signal Transduction; Thymosin | 2019 |
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.
Topics: Animals; Collagen; Disease Models, Animal; Fibronectins; Fibrosis; Kidney; Kidney Diseases; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myofibroblasts; Oligopeptides; Plasminogen Activator Inhibitor 1; Prolyl Oligopeptidases; Serine Endopeptidases; Serine Proteinase Inhibitors; Thymosin; Time Factors; Ureteral Obstruction; Urological Agents | 2013 |
N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice.
Topics: Actins; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Chemokine CCL2; Collagen Type IV; Fibrosis; Immunohistochemistry; Inflammation; Kidney Diseases; Lymphocytes; Macrophages; Male; Mice; Mice, Inbred BALB C; Muscle, Smooth; Oligopeptides; Real-Time Polymerase Chain Reaction; Ureteral Obstruction | 2015 |
N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Disease Models, Animal; Extracellular Matrix Proteins; Fibrosis; Indoles; Kidney; Kidney Diseases; Male; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oligopeptides; Peptidyl-Dipeptidase A; Prolyl Oligopeptidases; Serine Endopeptidases; Serine Proteinase Inhibitors; Signal Transduction; Thiazolidines; Transforming Growth Factor beta1; Ureteral Obstruction | 2018 |
Effects of N-acetyl-seryl-asparyl-lysyl-proline on blood pressure, renal damage, and mortality in systemic lupus erythematosus.
Topics: Albuminuria; Animals; Blood Pressure; Female; Fibrosis; Hypertension; Kidney; Kidney Diseases; Lupus Erythematosus, Systemic; Mice; Oligopeptides; Survival Analysis; T-Lymphocytes | 2017 |